KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBITDA (2017 - 2025)

Historic EBITDA for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$15.4 million.

  • Aquestive Therapeutics' EBITDA fell 3420.8% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 9600.2%. This contributed to the annual value of -$44.1 million for FY2024, which is 46082.59% down from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' EBITDA is -$15.4 million, which was down 3420.8% from -$13.5 million recorded in Q2 2025.
  • Aquestive Therapeutics' EBITDA's 5-year high stood at $8.1 million during Q1 2023, with a 5-year trough of -$28.9 million in Q4 2021.
  • In the last 5 years, Aquestive Therapeutics' EBITDA had a median value of -$12.8 million in 2024 and averaged -$12.0 million.
  • In the last 5 years, Aquestive Therapeutics' EBITDA surged by 16102.87% in 2023 and then crashed by 46555.28% in 2024.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' EBITDA stood at -$28.9 million in 2021, then surged by 57.33% to -$12.4 million in 2022, then soared by 34.33% to -$8.1 million in 2023, then crashed by 110.27% to -$17.1 million in 2024, then increased by 9.43% to -$15.4 million in 2025.
  • Its EBITDA was -$15.4 million in Q3 2025, compared to -$13.5 million in Q2 2025 and -$22.9 million in Q1 2025.